Array
(
)
1
> Antibacterial>MMV371

Antibacterial

MMV371 View larger

MMV371

AOB18144

CAS: 1080645-02-8

 

Chemical Name: mCBE161; 3-((1r,4r)-4-(4-Chlorophenyl)cyclohexyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate

More details

2500 Items

Molarity Calculation Cart®

HOW TO ORDER

$87.00

$87.00 per mg

Quantity Discount Table - Order More To Get More Price Discount

QuantitymgUnit Price ($/mg or $/Unit)Final Price
15 $73.95 Total: $369.75
110 $62.64 Total: $626.40
125 $53.07 Total: $1,326.75
150 $45.24 Total: $2,262.00
1100 $39.15 Total: $3,915.00

Data sheet

Molecular FormulaC24H21ClO4
Molecular Weight408.88
CAS Numbers1080645-02-8
Storage Condition0°C (short term), -20°C (long term), desiccated
SolubilityDMSO
Purity98% by HPLC
SynonymMMV 371; MMV-371; mCBE161
IUPAC/Chemical Name3-((1r,4r)-4-(4-Chlorophenyl)cyclohexyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate
References1) Myriam El Gaaloul et. al.; Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile, Malaria Journal volume 23, Article number: 315 (2024)

More info

MMV371 is a long-acting injectable (LAI) antimalarial drug developed by Medicines for Malaria Venture (MMV). It is designed to provide extended protection against malaria with a single intramuscular dose.

Mechanism of Action

MMV371 is a prodrug of atovaquone, a well-established antimalarial agent. By attaching an ester-linked acetyl group to atovaquone, MMV371 is designed to remain inactive until it is metabolized in the body. This modification allows for prolonged circulation and extended pharmacological activity. In preclinical studies, a single intramuscular injection of MMV371 maintained atovaquone levels above the minimum effective concentration for up to 69 days, compared to 21 days with atovaquone alone. Scripps Research

Target Parasites

MMV371 targets the mitochondrial cytochrome bc1 complex, inhibiting the electron transport chain in the malaria parasite. This action disrupts energy production, leading to parasite death. It is effective against both Plasmodium falciparum and Plasmodium vivax, the two most prevalent malaria parasites. mmv.org

Clinical Development

A Phase 1 clinical trial for MMV371 commenced in 2024 in Nottingham, UK. The trial aims to assess the drug's safety, tolerability, and pharmacokinetics in healthy volunteers. Pending successful outcomes, clinical trials in malaria-endemic regions are anticipated to begin in 2026. Scripps Research

Potential Benefits

  • Extended Protection: A single dose could offer up to three months of protection against malaria.

  • Simplified Dosing: Reduces the need for daily medication, improving patient compliance.

  • Asymptomatic Infection Clearance: Potential to clear asymptomatic malaria infections, reducing transmission.

  • Affordability: Designed to be cost-effective, making it accessible in resource-limited settings. Quotient Sciences